{
    "2021-09-16": [
        [
            {
                "time": "2023-10-05",
                "original_text": "AbbVie Submits Upadacitinib Applications In US, Europe For Ulcerative Colitis",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Upadacitinib",
                        "Applications",
                        "US",
                        "Europe",
                        "Ulcerative Colitis"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "2 Embarrassingly Cheap Dividend Stocks to Buy",
                "features": {
                    "keywords": [
                        "Cheap",
                        "Dividend",
                        "Stocks",
                        "Buy"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "general"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Regulatory",
                        "Applications",
                        "FDA",
                        "EMA",
                        "Upadacitinib",
                        "RINVOQ®",
                        "Treatment",
                        "Adults",
                        "Moderately",
                        "Severely",
                        "Active",
                        "Ulcerative",
                        "Colitis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}